[go: up one dir, main page]

AR124688A2 - Una pirimidina sulfonamida o un tautómero del mismo, o una sal farmacéuticamente aceptable del mismo - Google Patents

Una pirimidina sulfonamida o un tautómero del mismo, o una sal farmacéuticamente aceptable del mismo

Info

Publication number
AR124688A2
AR124688A2 ARP220100128A ARP220100128A AR124688A2 AR 124688 A2 AR124688 A2 AR 124688A2 AR P220100128 A ARP220100128 A AR P220100128A AR P220100128 A ARP220100128 A AR P220100128A AR 124688 A2 AR124688 A2 AR 124688A2
Authority
AR
Argentina
Prior art keywords
compound
tautomer
pharmaceutically acceptable
acceptable salt
pyrimidine sulfonamide
Prior art date
Application number
ARP220100128A
Other languages
English (en)
Inventor
Iain Alastair Stewart Walters
Mark Richard Ebden
Craig Robert Stewart
Alan Robert Steven
Stephen Connolly
Paula Margaret Tomlin
Andrew John Williams
Thomas Langer
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR124688A2 publication Critical patent/AR124688A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
    • C07C69/92—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with etherified hydroxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/20—Free hydroxyl or mercaptan
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/24—Radicals substituted by singly bound oxygen or sulfur atoms esterified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/26—Radicals substituted by doubly bound oxygen or sulfur atoms or by two such atoms singly bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/78—Benzoic acid esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/12—Radicals substituted by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

Abstract

Se proporciona un compuesto que es (a) una pirimidina sulfonamida de fórmula (1) o un tautómero del mismo, o (b) una sal farmacéuticamente aceptable del mismo, formas cristalinas del compuesto, procesos para obtener el compuesto, intermediarios farmacéuticos utilizados en la fabricación del compuesto y composiciones farmacéuticas que contienen el compuesto. El compuesto es útil en el tratamiento de una enfermedad / afección en la cual resulta beneficiosa la modulación de la actividad del receptor de quimioquina.
ARP220100128A 2011-07-12 2022-01-21 Una pirimidina sulfonamida o un tautómero del mismo, o una sal farmacéuticamente aceptable del mismo AR124688A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161506737P 2011-07-12 2011-07-12

Publications (1)

Publication Number Publication Date
AR124688A2 true AR124688A2 (es) 2023-04-26

Family

ID=46513787

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP120102531A AR087168A1 (es) 2011-07-12 2012-07-12 Compuesto derivado de pirimidina sulfonamida
ARP220100128A AR124688A2 (es) 2011-07-12 2022-01-21 Una pirimidina sulfonamida o un tautómero del mismo, o una sal farmacéuticamente aceptable del mismo

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP120102531A AR087168A1 (es) 2011-07-12 2012-07-12 Compuesto derivado de pirimidina sulfonamida

Country Status (38)

Country Link
US (3) US8735413B2 (es)
EP (2) EP2731945A1 (es)
JP (2) JP6006308B2 (es)
KR (1) KR101946664B1 (es)
CN (1) CN103781781B (es)
AR (2) AR087168A1 (es)
AU (2) AU2012282316B2 (es)
BR (1) BR112014000636B1 (es)
CA (1) CA2841859C (es)
CL (1) CL2014000079A1 (es)
CO (1) CO6852072A2 (es)
CR (1) CR20140007A (es)
CU (2) CU24292B1 (es)
CY (1) CY1124329T1 (es)
DK (1) DK3255043T3 (es)
DO (1) DOP2013000308A (es)
EA (1) EA027821B1 (es)
EC (1) ECSP14013130A (es)
ES (1) ES2861927T3 (es)
HR (1) HRP20210413T1 (es)
HU (1) HUE053703T2 (es)
IL (1) IL230398A (es)
LT (1) LT3255043T (es)
MX (2) MX342874B (es)
MY (1) MY180039A (es)
NI (1) NI201400002A (es)
PE (2) PE20141944A1 (es)
PH (1) PH12014500107A1 (es)
PL (1) PL3255043T3 (es)
PT (1) PT3255043T (es)
RS (1) RS61608B1 (es)
SG (1) SG10201605619XA (es)
SI (1) SI3255043T1 (es)
SM (1) SMT202100173T1 (es)
TW (2) TWI633098B (es)
UY (1) UY34191A (es)
WO (1) WO2013008002A1 (es)
ZA (1) ZA201401059B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013000788A2 (pt) 2010-07-13 2017-09-26 Astrazeneca Ab formas cristalinas de n-[2-[[(2,3-diflúor fenil) metil] tio]-6-{[(1r,2s)-2,3-di-hidroxi-1-metil propil] oxi}-4-pirimidil]-1-azetidino sulfonamida
CA2841859C (en) * 2011-07-12 2021-03-09 Astrazeneca Ab N- (6- ( (2r,3s) -3,4-dihydroxybutan-2-yloxy) -2- (4 - fluorobenzylthio)pyrimidin- 4 - yl) -3- methylazetidine- 1 - sulfonamide as chemokine receptor modulator
EP2740458B1 (en) * 2012-12-06 2016-08-03 IP Gesellschaft für Management mbH Packaging comprising forms of sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide
CA3017345A1 (en) * 2016-03-11 2017-09-14 Ardea Biosciences, Inc. Cxcr-2 inhibitors for treating crystal arthropathy disorders
AR112801A1 (es) * 2017-09-12 2019-12-11 Ardea Biosciences Inc Inhibidores de cxcr-2 para tratar trastornos
WO2020249688A1 (en) 2019-06-12 2020-12-17 Nouryon Chemicals International B.V. Process for the production of diacyl peroxides
EP3983340B1 (en) * 2019-06-12 2023-08-02 Nouryon Chemicals International B.V. Method for isolating carboxylic acid from an aqueous side stream
EP3983370B1 (en) 2019-06-12 2023-08-02 Nouryon Chemicals International B.V. Process for the production of diacyl peroxides
ES2961184T3 (es) 2019-06-12 2024-03-08 Nouryon Chemicals Int Bv Proceso para la producción de peróxidos de diacilo
WO2020249689A1 (en) 2019-06-12 2020-12-17 Nouryon Chemicals International B.V. Process for the production of peroxyesters

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3457278A (en) * 1964-10-15 1969-07-22 Geigy Chem Corp Cyclopropyl-4-sulfanilamido-pyrimidines
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
BR9707495A (pt) 1996-02-13 1999-07-27 Zeneca Ltd Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
AU719327B2 (en) 1996-03-05 2000-05-04 Astrazeneca Ab 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
FI981521A0 (fi) * 1998-07-01 1998-07-01 Orion Corp Substituoidut beta-diketonit ja niiden käyttö
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
IL152682A0 (en) 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
WO2002004434A1 (en) 2000-07-07 2002-01-17 Angiogene Pharmaceuticals Limited Colchinol derivatives as vascular damaging agents
KR20030022264A (ko) 2000-07-07 2003-03-15 앤지오젠 파마슈티칼스 리미티드 신생 혈관 형성 억제제인 콜치놀 유도체
GB0217431D0 (en) 2002-07-27 2002-09-04 Astrazeneca Ab Novel compounds
GB0419235D0 (en) * 2004-08-28 2004-09-29 Astrazeneca Ab Compounds
KR101280095B1 (ko) * 2004-08-28 2013-09-09 아스트라제네카 아베 케모킨 수용체 조절제로서의 피리미딘 술폰아미드 유도체
CA2637631C (en) * 2006-01-19 2014-04-29 Orchid Research Laboratories Limited Pyrimidine compounds and uses thereof
WO2008157273A1 (en) * 2007-06-14 2008-12-24 Smithkline Beecham Corporation Chemical compounds
RU2011101661A (ru) 2008-07-16 2012-08-27 Астразенека Аб (Se) Пиримидилсульфонамидное производное и его применение для лечения хемокин-опосредованных заболеваний
CN102105434A (zh) 2008-07-25 2011-06-22 巴斯夫欧洲公司 3-氨基甲基-1-环己基胺及其生产方法
BR112013000788A2 (pt) * 2010-07-13 2017-09-26 Astrazeneca Ab formas cristalinas de n-[2-[[(2,3-diflúor fenil) metil] tio]-6-{[(1r,2s)-2,3-di-hidroxi-1-metil propil] oxi}-4-pirimidil]-1-azetidino sulfonamida
CA2841859C (en) * 2011-07-12 2021-03-09 Astrazeneca Ab N- (6- ( (2r,3s) -3,4-dihydroxybutan-2-yloxy) -2- (4 - fluorobenzylthio)pyrimidin- 4 - yl) -3- methylazetidine- 1 - sulfonamide as chemokine receptor modulator

Also Published As

Publication number Publication date
CU20140004A7 (es) 2014-05-27
PL3255043T3 (pl) 2021-07-12
TW201825479A (zh) 2018-07-16
DOP2013000308A (es) 2014-02-28
CN103781781B (zh) 2015-08-26
PT3255043T (pt) 2021-03-29
UY34191A (es) 2013-02-28
IL230398A (en) 2017-10-31
CO6852072A2 (es) 2014-01-30
HUE053703T2 (hu) 2021-07-28
ZA201401059B (en) 2017-09-27
EP3255043A3 (en) 2018-04-18
DK3255043T3 (da) 2021-03-29
NI201400002A (es) 2016-02-16
SMT202100173T1 (it) 2021-05-07
CA2841859A1 (en) 2013-01-17
CN103781781A (zh) 2014-05-07
KR20140037915A (ko) 2014-03-27
HK1245779A1 (en) 2018-08-31
JP2016190864A (ja) 2016-11-10
US20160108023A1 (en) 2016-04-21
MY180039A (en) 2020-11-20
CL2014000079A1 (es) 2014-06-27
CA2841859C (en) 2021-03-09
AU2016244246B2 (en) 2017-11-23
JP6261666B2 (ja) 2018-01-17
TWI633098B (zh) 2018-08-21
CY1124329T1 (el) 2022-07-22
PE20141944A1 (es) 2014-12-24
AR087168A1 (es) 2014-02-26
RS61608B1 (sr) 2021-04-29
ES2861927T3 (es) 2021-10-06
EA027821B1 (ru) 2017-09-29
SG10201605619XA (en) 2016-08-30
MX2013015085A (es) 2014-01-24
US8735413B2 (en) 2014-05-27
MX353334B (es) 2018-01-09
JP2014520838A (ja) 2014-08-25
US9975881B2 (en) 2018-05-22
NZ619001A (en) 2016-05-27
AU2012282316A1 (en) 2013-05-02
PE20181069A1 (es) 2018-07-04
CU20160083A7 (es) 2017-03-03
AU2012282316B2 (en) 2016-07-14
LT3255043T (lt) 2021-04-12
PH12014500107A1 (en) 2014-03-03
TW201311670A (zh) 2013-03-16
CR20140007A (es) 2014-05-14
KR101946664B1 (ko) 2019-02-11
EP3255043A2 (en) 2017-12-13
US20140228339A1 (en) 2014-08-14
EA201490077A1 (ru) 2014-10-30
EP2731945A1 (en) 2014-05-21
US9221782B2 (en) 2015-12-29
BR112014000636B1 (pt) 2022-08-30
ECSP14013130A (es) 2014-02-28
MX342874B (es) 2016-10-17
NZ719176A (en) 2017-11-24
AU2016244246A1 (en) 2016-10-27
JP6006308B2 (ja) 2016-10-12
US20130040926A1 (en) 2013-02-14
TWI659026B (zh) 2019-05-11
CU24292B1 (es) 2017-12-08
SI3255043T1 (sl) 2021-04-30
HRP20210413T1 (hr) 2021-05-14
BR112014000636A2 (pt) 2017-01-10
EP3255043B1 (en) 2021-01-20
WO2013008002A1 (en) 2013-01-17

Similar Documents

Publication Publication Date Title
AR124688A2 (es) Una pirimidina sulfonamida o un tautómero del mismo, o una sal farmacéuticamente aceptable del mismo
MX2014000536A (es) Compuestos de 4-piperidinilo para usarse como inhibidores de tanquirasa.
CR20160191A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
DOP2012000105A (es) Compuestos de espiropiperidina y uso farmaceutico del mismo para tratar la diabetes
CR20130560A (es) Compuestos de bezotiazol y su uso farmacéutico
CO6382125A2 (es) Inhibidores de proteína quinasa
CR20150050A (es) Sales y formas solidas de (s)-3-(4-((4-(morfolinometil) bencil) oxi)-1-oxoisoindolin-2-il) piperidin-2, 6-diona y composiciones que comprenden y métodos para utilizar las mismas
ECSP12011930A (es) Nuevos compuestos de espiropiperidina
AR079134A1 (es) Procedimiento para la preparacion de (4,6-diamino -2-(1-(2- fluorobencil )-1h- pirazolo (3,4-b) piridin-3-il) pirimidin -5-il) metil carbamato de metilo y su purificacion para su uso como principio activo farmaceutico
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
MX2016006336A (es) Compuestos pirazolopirimidina.
CO6480931A2 (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas.
CU20140072A7 (es) Derivados de dihidro-oxazina y dihidro-pirido-oxazina
PH12016502103A1 (en) Novel disubstituted 1,2, 4-triazine compound
EA201300250A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
MX349254B (es) Compuestos para el tratamiento del sindrome metabolico.
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.
UY31824A (es) Nuevos compuestos
AR083755A1 (es) Formas solidas del acido (s)-2-amino-3-(4-(-2-amino-6-((r)-1-(4-cloro-2-(3-metil-1h-pirazol-1-il)fenil)-2,2,2-trifluoroetoxi)pirimidin-4-il)fenil)propanoico
EA201400786A1 (ru) Карбоциклические нуклеозиды, их фармацевтическое применение и композиции
CO6382120A2 (es) Compuestos ciclopropilo
EA200802000A1 (ru) Фармацевтически приемлемые соли и полиморфные формы
CL2008002623A1 (es) Uso de urato oxidasa para el tratamiento o profilaxis de trastornos o secuelas indirectas del corazon provocados por sucesos isquemicos o de reperfusion.
CL2011000120A1 (es) Proceso de preparacion de compuestos 2-amino-tiazolonas sustituidas.